Agios Pharmaceuticals Inc

NASDAQ: AGIO
$29.03
+$0.23 (+0.8%)
Closing price April 17, 2024
Agios Pharmaceuticals Inc is a pioneering biopharmaceutical company based in Cambridge, Massachusetts, focusing on creating innovative medicines that target cellular metabolism. Its flagship product, PYRUKYND, is a groundbreaking treatment for hemolytic anemias, activating specific enzymes to combat the disease. Agios is also developing treatments for myelodysplastic syndrome and phenylketonuria, alongside research into combating polycythemia vera, a rare blood disorder, through preclinical studies. Founded in 2007, Agios is at the forefront of addressing complex diseases with cutting-edge science.
Thursday’s additional top analyst upgrades and downgrades were on Advance Auto Parts, AppLovin, Nio, Norfolk Southern, Norwegian Cruise Line, Quest Diagnostics, Salesforce, Sprouts Farmers Market,...
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Amazon.com, Edwards Lifesciences, Gilead Sciences, Mastercard and Pinterest.
Thursday’s top analyst upgrades and downgrades included AutoNation, Enbridge, Gap, JinkoSolar, Micron Technology, Nvidia, Tractor Supply, Twilio and Vertex Pharmaceuticals.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including American Airlines, Biogen, Dow, Medtronic and Zoom Video.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including BioCryst, Editas, Groupon, Sunrun, Twitter and more.
Agios Pharmaceuticals shares jumped on Monday after the company announced that it will be streamlining its portfolio.